Recombinant EPO therapy increases erythrocyte expression of complement regulatory proteins

American Journal of Kidney Diseases

Volumn 41, Issue 1, 2003, Pages 179-185

  Ohi, Hiroyuki ^a,b   Tamano, Mariko ^a,b   Sudo, Sukemasa ^a,b   Okada, Noriko ^a,b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

CD59; Complement receptor 1 (CR1); Decay accelerating factor (DAF); Hemodialysis (HD); Recombinant erythropoietin (rEPO)

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE; EVALUATION; HEMATOCRIT; HEMODIALYSIS; HEMOLYSIS; HUMAN; INHIBITION KINETICS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME;

EID: 0037228106     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50002     Document Type: Article

References (25)

1. Eschbach JW: The anemia of chronic renal failure. Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35:134-148, 1989
2. Eschbach JW, Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA: Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 276:653-658, 1967
3. Jacob HS, Eaton JW, Yawata Y: Shortened red blood cell survival in uremic patients: Beneficial and deleterious effects of dialysis. Kidney Int Suppl 2:S139-S143, 1975
4. Pascual M, Steiger G, Estreicher J, Macon K, Volanakis JE, Schifferli JA: Metabolism of complement factor D in renal failure. Kidney Int 34:529-536, 1988
5. Volanakis JE, Barnum SR, Giddens M, Galla JH: Renal filtration and catabolism of complement protein D. N Engl J Med 312:395-399, 1985
6. Cheung AK: Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1:150-161, 1990
7. Hakim RM: Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 44:484-494, 1993
8. Himmelfarb J, McMonagle E, Holbrook D, Hakim R: Increased susceptibility to erythrocyte C5b-9 deposition and complement-mediated lysis in chronic renal failure. Kidney Int 55:659-666, 1999
9. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF: Isolation of a human erythrocyte membrane glycoprotein with decay accelerating activity for C3 convertases of the complement system. J Immunol 129:184-189, 1982
10. Okada N, Harada R, Fujita T, Okada H: A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1:205-208, 1989
11. Okada N, Harada R, Fujita T, Okada H: Monoclonal antibodies capable of causing hemolysis of neuraminidasetreated human erythrocytes by homologous complement. J Immunol 143:2262-2266, 1989
12. Sugita Y, Tobe T, Oda E, et al: Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. J Biochem (Tokyo) 106:555-557, 1989
13. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ: Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84:7-17, 1989
14. Davies A, Simmons DL, Hale G, et al: CD59, a Ly-6-like protein expressed in human lymphoid cells, regulates the actions of the complement membrane attack complex on homologous cells. J Exp Med 170:637-654, 1989
15. Hebert LA: The clearance of immune complexes from the circulation of man and other primates. Am J Kidney Dis 17:352-361, 1991
16. Hebert LA, Cosio FG, Birmingham DJ, Mahan JD: Biologic significance of the erythrocyte complement receptor: A primate perquisite. J Lab Clin Med 118:301-308, 1991
17. Hebert LA, Birmingham DJ, Dillon JJ, Cosio FG, Shen XP: Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1(CD35). J Am Soc Nephrol 4:1786-1791, 1994
18. Kinoshita T, Medof ME, Silber R, Nussenzweig V: Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 162:75-92, 1985
19. Erslev AJ: Erythropoietin. N Engl J Med 324:1339-1344, 1991
20. Hebert LA, Birmingham DJ, Shen X-P, Cosio FG: Stimulating erythropoiesis increases complement receptor expression on primate erythrocytes. Clin Immunol Immunopathol 62:301-306, 1992
21. Pascual M, Danielsson C, Steiger G, Schifferli JA: Proteolytic cleavage of CR1 on human erythrocytes in vivo: Evidence for enhanced cleavage in AIDS. Eur J Immunol 24:702-708, 1994
22. Wilson JG, Murphy EE, Wong WW, Klickstein LB, Weis JH, Fearon DT: Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med 164:50-59, 1986
23. Langsdorf LJ, Zydney AL: Effect of uremia on the membrane transport characteristics of red blood cells. Blood 81:820-827, 1993
24. Yamashina M, Ueda E, Kinoshita T, et al: Inherited complement deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 323:1184-1189, 1990
25. Endoh M, Yamashina M, Ohi H, et al: Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 94:182-188, 1993